Maxim upgraded Synaptogenix to Buy from Hold with a $14 price target. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on SNPX: Synaptogenix announces FDA approved IND application for Bryostatin-1 Synaptogenix CEO Dr. Tuchman’s Tenure Extended Through 2024 Disclaimer & DisclosureReport an Issue
